The Greater New Haven Biotechnology Committee will present a symposium, "Anatomy of a Venture Deal," at Yale on Wednesday, May 21.
"One of the best ways that New Haven and the surrounding area can profit from the more than $200 million dollars spent on life sciences research at Yale is by forming new biotechnology ventures," says Gregory E. Gardiner, director of the Office of Cooperative Research and chair of the Greater New Haven Biotechnology Committee. "We can help promote new venture formation by having people who have been through this process relate their experiences so others can learn from them."
Featured speakers at the symposium will be Tim Howe, a partner with Collinson, Howe and Lennox, a venture capital group based in Stamford, Connecticut; and Dr. Leonard Bell, president and chief executive officer of Alexion Pharmaceuticals at Science Park in New Haven, will speak. Dr. Bell, a 1984 graduate of the School of Medicine, previously served on the Yale internal medicine faculty in the cardiology section.
"Alexion is one of seven biotech ventures in the state of Connecticut, and one of three that has gone public based on Yale technology," Mr. Gardiner points out. "Collinson, Howe & Lennox have invested in two of the Yale-based companies, Alexion and Neurogen."
The symposium will be held 8 a.m.-9:30 a.m. in Rm. 305 of the Bass Center, 266 Whitney Ave. It is free and open to the Yale medical and University communities and interested members of the general public. Reservations, although not required, are suggested; they may be made by calling Barbara at 932-7126.